Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.77 USD
Change Today -0.06 / -3.28%
Volume 1.4M
OCLS On Other Exchanges
Symbol
Exchange
OCLS is not on other exchanges.
As of 5:20 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

oculus innovative sciences i (OCLS) Key Developments

Oculus Innovative Sciences, Inc. to Report Q1, 2016 Results on Jul 30, 2015

Oculus Innovative Sciences, Inc. announced that they will report Q1, 2016 results at 1:30 PM, Pacific Daylight on Jul 30, 2015

Oculus Innovative Sciences, Inc., Q1 2016 Earnings Call, Jul 30, 2015

Oculus Innovative Sciences, Inc., Q1 2016 Earnings Call, Jul 30, 2015

Oculus Innovative Sciences, Inc. Receives New U.S. Patent for Microcyn Technology in Treatment of Atopic Dermatitis

Oculus Innovative Sciences, Inc. announced the receipt of a new U.S. patent for the use of the Microcyn Technology hypochlorous acid in the treatment and mitigation of atopic dermatitis.

Oculus Innovative Sciences Regains Compliance With NASDAQ Minimum Bid Price Rule

Oculus Innovative Sciences, Inc. announced that it received a formal determination letter from The NASDAQ Stock Market LLC (NASDAQ) notifying the company that it is now compliant with the minimum bid price requirement for continued listing on the NASDAQ Capital Market and is no longer subject to delisting at this time. The NASDAQ staff has determined that for the 10 consecutive business days, from June 3, 2015, to June 16, 2015, the closing bid price of the company's common stock has been at $1.00 per share or greater. As announced on March 12, 2015, the company received a letter from NASDAQ, indicating that it did not comply with the $1.00 minimum closing bid price requirement for its common stock for continued listing on the NASDAQ Capital Market. NASDAQ granted the company a compliance period of 180 calendar days, or until September 2, 2015, to regain compliance with the listing rule. Because the company has regained compliance, the matter is now closed.

Oculus Innovative Sciences, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2015; Announces Impairment Loss on Long-Term Investment for the Fourth Quarter Ended March 31, 2015

Oculus Innovative Sciences, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended March 31, 2015. For the quarter, the company announced total revenues of $3,980,000 compared to $2,914,000 for the same period a year ago. Loss from operations was $1,652,000 compared to $2,108,000 for the same period a year ago. Net loss was $1,502,000 or $0.11 per basic and diluted share compared to net income of $7,457,000 or $0.99 per diluted share for the same period a year ago. Non-GAAP loss from operations minus non-cash expenses (EBITDAS) was $1,174,000 compared to $1,698,000 for the same period a year ago. Non-GAAP net loss minus non-cash expenses was $1,190,000 compared to $1,700,000 for the same period a year ago. Increase in net loss is primarily due to the one-time gain of $11.1 million recorded in the three months ended March 31, 2014, related to Oculus' investment in Ruthigen. For the full year, the company announced total revenues of $13,854,000 compared to $13,668,000 for the same period a year ago. Loss from operations was $6,659,000 compared to $6,051,000 for the same period a year ago. Net loss was $8,203,000 or $0.85 per basic and diluted share compared to net income of $3,735,000 or $0.54 per basic and diluted share for the same period a year ago. Non-GAAP loss from operations minus non-cash expenses (EBITDAS) was $4,635,000 compared to $4,316,000 for the same period a year ago. Non-GAAP net loss minus non-cash expenses was $4,693,000 compared to $4,591,000 for the same period a year ago. For the fourth quarter ended March 31, 2015, the company announced impairment loss on long-term investment of $4,650,000.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OCLS:US $1.77 USD -0.06

OCLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,852 JPY 0.00
Henry Schein Inc $146.76 USD +0.22
Integra LifeSciences Holdings Corp $64.00 USD -0.18
Patterson Cos Inc $49.77 USD +0.83
Smith & Nephew PLC 1,167 GBp +32.00
View Industry Companies
 

Industry Analysis

OCLS

Industry Average

Valuation OCLS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.7x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OCULUS INNOVATIVE SCIENCES I, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.